Each program appears to increase optionality and reduce risk. 👉 This is where strategic overload begins 👉 The story shifts from decisive execution to optional exploration 👉 The perceived execution risk increases initiatives, demonstrating alignment becomes harder. 👉 Strategic overload does not make a company look incompetent

All masterclasses — past and upcoming — are included with Premium Membership. GPCR–lipid raft associations and the expanding therapeutic landscape of extra-oral bitter taste receptors, including Interpretation risk is increasing. Dr.

announced a strategic partnership with Eurofins DiscoverX , a global leader in GPCR product solutions including Their cell-based assays support a wide range of mechanisms of action, including cAMP accumulation, β-arrestin

Orthosteric antagonists remain theoretically unlimited  — competition continues as concentration increases becomes critical in both screening strategy and therapeutic positioning As ligand diversity expands — including

Each course page includes a short trailer, defined learning outcomes, and explicit take-home messages All courses remain included in Premium Membership. Submissions are welcome across formats including Original Research, Reviews, Methods, Perspectives, Hypothesis GPCR University courses — now included in Premium. Reduce external training spend while increasing scientific depth.

👉 Strong biotech startups do not fail because the science is weak or the team is incapable. Meetings increase. Slides improve. Activity intensifies. Activity increases, but clarity erodes , and the company becomes reactive instead of intentional. Scientific nuance starts to feel inconvenient. strategically settled. 4️⃣ They protect decision quality under pressure. 👉 As fundraising intensity increases

Kenakin acknowledges the increasing utility of in silico alerts in early decision-making, arming medicinal

confirms Q4 2025 results call; Novo Nordisk explores monthly GLP-1 acquisition; 2025 Fellows announced, including FAQ 🔹 What’s included?

. 👉 This kind of failure is hard to detect because it hides behind familiar patterns: Incremental scope Activity increases while coherence declines . Effort increases.

unexpected distribution profiles forced complete strategic pivots Plasma concentration alone is an incomplete

Business development conversations feel inconsistent, even when the company and the science have not This inconsistency is not random. meetings with different interpretations of what the company actually is , which slows momentum and increases Each external interaction becomes reactive, shaped more by incoming questions than by strategic intent Scientific depth increases complexity.

. ✅ Early strategic decision-making does not guarantee success, but it dramatically increases the odds Biotech teams operate across disciplines, timelines, and incentives.

It is building a team that cannot operate when answers are incomplete. ✅ This is where survival is decided They look for certainty before committing. 👉 This is not incompetence. Progress depends on decisions made with incomplete information. The Difference Between Competent and Useful in Early Stage Biotech As uncertainty increases, a subtle

Common signals include: 👉 Patents focused on one indication, while the business story targets another Typical problem areas include: 👉 University licenses with complex or restrictive terms 👉 Unclear rights That uncertainty increases perceived risk, even if the underlying science is compelling. Intellectual property is increasingly evaluated together with development plans and commercial intent

. 👉 BD partners disengage  because timing and readiness seem inconsistent. 👉 Teams hedge their work But what kills momentum is timing inconsistency . 👉 Without a defined decision cadence: Choices get conversations that lack mutual timing expectations internal teams working with partial context narrative inconsistency

Premium Membership pricing increases in 2026, and the 67% Terry’s Corner discount is going away. This year brought 20+ podcast episodes, 40% audience growth, and an 811% increase in new listeners. contributors Launch of The Foundry , supporting strategy and CRO alignment In-person community moments, including

You may see: Early stopping → potency distortions Different stopping times → incomparable datasets Curve

In this episode, JB pulls the curtain back on the mindset and tactics he’s used for years—including the

AI-assisted probe design Multi-receptor visualization in complex tissue The dream is ambitious and increasingly

They are signs of strategic incompleteness .

Live-cell high-content screening (HCS) offers an increasingly valuable alternative. , 16 synthetic cannabinoid receptor agonists (SCRAs) were evaluated using a CB2 live-cell HCS assay incorporating Because imaging is captured across thousands of intact cells, each measurement incorporates receptor Moderate displacement (50–70%) :  AV18A (68.83%), AV11 (60.78%) Low displacement (<50%) :  Compounds including Representative HCS images illustrating CELT331 binding (red) and Hoechst-stained nuclei (blue) across increasing

When David later shared early data — including a moment where he realized he could image an entire islet Antibodies As JB continued exploring the biology, a major obstacle emerged: validated antibodies for GPCRs, including GLP-1R, were inconsistent and incompatible with high-resolution imaging. David picked up unexpected chemistry insights — including a well-loved lesson involving acetonitrile They’re also performing increasingly complex imaging experiments that capture receptor dynamics in intact

FAQ 🔹 What’s included?

Orthosteric dose increases drive continuously stronger responses; NAMs and PAMs have structural ceilings A partial agonist appears neutral until expression or coupling is increased. Dr. NAMs, PAMs, and Subtle Mechanistic Traps Modulators are frequently labeled correctly but characterized incompletely These nonlinearities matter: Competitive inhibition decreases as substrate increases. Uncompetitive inhibition strengthens as substrate increases—opposite of intuition.

In research, including the GPCR world collaboration isn’t a luxury. It’s survival. To understand how incretin receptors behave in intact tissue, Hodson needed people who saw problems differently Hodson’s group felt the impact directly: imaging incretin receptors in intact islets and brain slices And interactions with GLP-1 pathways were inconsistent.

several performance-limiting factors: variable cell behavior, imaging artifacts, batch effects, and incomplete In this blog, you’ll learn:  How HCS works and why it is increasingly central to GPCR-based drug discovery However, their limitations become increasingly important as drug discovery moves toward high-information Key limitations of radioligand assays include:  • No spatial information  — signals are measured in bulk Incorporating internal controls, including known agonists or antagonists, allows normalization and facilitates

Here, the Schild plot becomes a diagnostic tool  rather than a checkbox test: Slopes >1  often mean incomplete Common revelations include: Mixtures of receptor subtypes  producing hybrid response patterns. Incomplete equilibration , where kinetics distort linearity.

In research, acting on incomplete or shaky data can destroy your credibility. Startups demand something different: ✅ Clarity of direction even when the picture is incomplete.

scientists embedded as “connectors” between programs This design had a strategic effect : talent density increased notes that the absence of individual ownership over physical space or specialized equipment removed the incentives Biotech teams, CRO alliances, and academic consortia face the same challenge: how to align incentives

These weren’t quaint inconveniences. They shaped how questions were asked.